Rosiglitazone (PPARγ-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model

Diabetes, Obesity and Metabolism

Volumn 5, Issue 1, 2003, Pages 45-50

  Levi, Z ^a   Shaish, A ^b,c   Yacov, N ^b,c   Levkovitz, H ^b   Trestman, S ^a   Gerber, Y ^b,c   Cohen, H ^b,c   Dvir, A ^b,c   Rhachmani, R ^a   Ravid, M ^b,c   Harats, D ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b MEIR MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Apolipoprotein E; Atherosclerosis; Low dose streptozotocin; PPAR ; Rosiglitazone

Indexed keywords

APOLIPOPROTEIN E; GLUCOSE; LIPID; LOW DENSITY LIPOPROTEIN RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; STREPTOZOCIN; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CELL RECEPTOR; CHOLESTEROL; FIBRINOLYTIC AGENT; THIAZOLE DERIVATIVE; TRANSCRIPTION FACTOR; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ATHEROSCLEROSIS; ARTERY WALL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MOUSE; NONHUMAN; SEX DIFFERENCE; ANIMAL; AORTA DISEASE; ARTERIOSCLEROSIS; BLOOD; DIABETIC ANGIOPATHY; DRUG POTENTIATION; EXPERIMENTAL DIABETES MELLITUS; MALE; METABOLISM; PATHOLOGY;

ANIMALS; AORTIC DISEASES; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; BLOOD GLUCOSE; CHOLESTEROL; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; FIBRINOLYTIC AGENTS; MALE; MICE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; TRIGLYCERIDES;

EID: 0037240841     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.2003.00240.x     Document Type: Article

References (21)

1. McGuire MD, Christopher B, Granger M, Darren K. Diabetes and ischemic heart disease. Am Heart J 1999; 138: S366-S375.
2. Birman EL. George Lyman Duff Memorial Lecture: atherogenesis in diabetes. Arteroscler Thromb Vasc Biol 1992; 12: 647-656.
3. Keaney FJ, Localzo J. Diabetes, oxidative stress and platelet activation. Circulation 1999; 99: 189-191.
4. Reaven GM. Role of insulin resistance in human disease. Diabetes 1998; 37: 1595-1607.
5. Reginato MJ, Lazar MA. Mechanisms by which thiazolidiones enhance insulin action. TEN 1999; 10: 9-13.
6. Kurtz WT, Gardner DG. Transcription-modulating drugs: new frontier in the treatment of essential hypertension. Hypertension 1998; 32: 380-386.
7. Jiang C, Ting AT, Seed B. PPARγ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82-86.
8. Ricote M, Li AC, Wilson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor gamma is a negative regulator of macrophages activation. Nature 1998; 391: 79-82.
9. Marx N, Schonbeck U, Lazar MA, Libby P, Plutzky J. Peroxisome proliferator-activated receptor gama activators inhibits gene expression and migration in vascular smooth muscle cells. Circ Res 1998; 83: 1097-1103.
10. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J. Macrophages in human atheroma contain PPARgama: differentiation dependent peroxisome proliferator-activated receptor gama expression and reduction of MMP-9 activity through PPARgama activation in mononuclear phagocytes in vitro. Am J Pathol 1998; 153: 17-23.
11. Tontonoz P, Nagy L, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgama. Cell 1998; 93: 229-240.
12. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARgama promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998; 93: 241-252.
13. Chinetti G, Lestavel S, Bocher V et al. PPAR alpha and PPAR gama activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABC1 pathway. Nature Med 2000; 7: 53-58.
14. Moore KJ, Rosen ED, Fitzgeerald ML et al. The role of PPARγ in macrophage differentiation and cholesterol uptake. Nature Med 2000; 7: 41-47.
15. Andrew C, Li KK, Brown MJ, Silverstre TM, Palinsky WW, Glass CK. Peroxisome proliferator activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2000; 106: 523-531.
16. Claudel T, Leibowitz MD, Fievet C et al. Reduction of atherosclerosis in apolipoprotein-E knockout mice by activation of the retinoid X receptor. Proc Natl Acad Sci USA 2001; 98: 2610-2615.
17. Keren P, George J, Shaish A et al. Effect of hyperglycemia and hyperlipidemia on atherosclerosis in LDL receptor-deficient Mice. Diabetes 2000; 49: 1064-1069.
18. Collins AR, Meehan WP, Kintscher U et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and non diabetic low density lipoprotein receptor deficient mice. Arteroscler Thromb Vasc Biol 2001; 21: 365-371.
19. Chen Z, Ishibishi S, Perrey S et al. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice. Arteroscler Thromb Vasc Biol 2001; 21: 372-377.
20. O'Brien BA, Harmon BV, Carmon DP, Allan DJ. Beta cell appoptosis is responsible for the development of IDDM in the multiple low-dose streptozotocin model. J Pathol 1996; 178: 176-181.
21. Takamura T, Ando H, Nagai Y, Yamashita H, Nohara E, Kobayashi K. Pioglitazone prevents mice from multiple low-dose streptozotocin insulinitis and diabetes. Diabetes Res Clin Pract 1999; 44: 107-114.